The market for sepsis and septic shock across the seven major pharmaceutical markets of the US, France, Germany, Italy, Spain, the UK, and Japan is expected to reach $5.9bn by 2026, according to a report by GlobalData.
Titled ‘Opportunity Analyzer: Sepsis and Septic Shock – Opportunity Analysis and Forecasts to 2026’ the report forecasts the sepsis and septic shock market to witness a compound annual growth rate (CAGR) of 7.9%, growing from $2.8bn in 2016.
Annual sales of sepsis drugs across the 7MM were approximately $2.2bn in 2016, while those of septic shock drugs were $600m.
Sepsis, a complex disease that causes organ dysfunction(s), has a high level of unmet need due to the absence of licensed products specific to the disease treatment across the 7MM.
Four new first-in-class pipeline drugs, namely BMS-936559, recAP, Traumakine, and CYT107, while three improved therapeutics, namely selepressin, thrombomodulin and cefiderocol are expected to be launched in the market in future, which will in turn drive the market growth.
The US market will witness the launch of two medical devices in the future, namely Toraymyxin and CytoSorb.
Sepsis treatments currently in pipeline target disseminated intravascular coagulopathy, acute lung injury, and acute kidney injury, but future opportunities will be in the development of novel therapies targeting comorbid conditions, says Christopher Pace, Director of the Infectious Disease team at GlobalData.
Involvement of multiple organs in sepsis and septic shock, however, poses a major hindrance to the development of safe, effective and tolerable treatment agents, the report adds.
